Mereo Biopharma Group Plc ADR (MREO) Stock: Evaluating the Market Performance
Moreover, the 36-month beta value for MREO is 0.96. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 3
Moreover, the 36-month beta value for MREO is 0.96. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 3
MREO has 36-month beta value of 0.96. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,”
The stock of Mereo Biopharma Group Plc ADR (NASDAQ: MREO) has increased by 0.55 when compared to last closing price of 3.76.Despite this, the company
The stock price of Mereo Biopharma Group Plc ADR (NASDAQ: MREO) has surged by 4.10 when compared to previous closing price of 3.66, but the
The 36-month beta value for MREO is at 0.89. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 3
In the past week, MREO stock has gone up by 5.15%, with a monthly gain of 16.57% and a quarterly surge of 46.76%. The volatility
© 2024, Powered by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.